Welireg
Payments companies reported to CMS as associated with Welireg. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Welireg, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Welireg
These are the largest totals companies reported as associated with Welireg. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Thai Ho | Scottsdale, AZ | Hematology & Oncology | $101,730.18 |
| Ronald Bukowski | Cleveland, OH | Hematology & Oncology | $65,777.50 |
| Minas Economides | New York, NY | Medical Oncology | $53,221.97 |
| Shahla Bari | Tampa, FL | Internal Medicine | $48,118.38 |
| Alton Sartor | Rochester, MN | Medical Oncology | $42,234.73 |
| Tomas Neilan | Boston, MA | Cardiovascular Disease | $40,320.00 |
| Putao Cen | Houston, TX | Medical Oncology | $37,214.22 |
| Sajeel Chowdhary | Tampa, FL | Neurology (Psychiatry & Neurology) | $32,645.25 |
| Kamran Shahid | Lake Charles, LA | Hematology & Oncology | $32,463.29 |
| Bradley Somer | Germantown, TN | Hematology & Oncology | $31,497.23 |
Prescribed Welireg?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.